Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
نویسندگان
چکیده
BACKGROUND Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure. METHODS AND RESULTS The circulating concentration of GDF-15 was measured at baseline (n=1734) and at 12 months (n=1517) in patients randomized in the Valsartan Heart Failure Trial (Val-HeFT). GDF-15 levels at baseline ranged from 259 to 25 637 ng/L and were abnormally high (>1200 ng/L) in 85% of patients. Higher levels were associated with features of worse heart failure and biomarkers of neurohormonal activation, inflammation, myocyte injury, and renal dysfunction. Baseline GDF-15 levels (per 100 ng/L) were associated with the risks of mortality (hazard ratio, 1.017; 95% confidence interval, 1.014 to 1.019; P<0.001) and first morbid event (hazard ratio, 1.020; 95% confidence interval, 1.017 to 1.023; P<0.001). In a comprehensive multiple-variable Cox regression model that included clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T, GDF-15 remained independently associated with mortality (hazard ratio, 1.007; 95% confidence interval, 1.001 to 1.014; P=0.02) but not first morbid event. At 12 months, the GDF-15 levels had increased by a similar amount in the placebo and valsartan groups (P=0.94). Increases in GDF-15 over 12 months were independently associated with the risks of future mortality and first morbid event also after adjustment for clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive protein, and high-sensitivity troponin T and their changes. CONCLUSIONS GDF-15 reflects information from several pathological pathways and provides independent prognostic information in heart failure. GDF-15 levels increase over time, suggesting that GDF-15 reflects a pathophysiological axis that is not completely addressed by the therapies prescribed in Val-HeFT.
منابع مشابه
Evaluation of Serum Ferritin Levels and its Relation with Severity and Duration of Hospitalization in Heart Failure Patients Admitted in Ganjavian Hospital, Ahvaz, Iran
Background: Cardiovascular diseases are one of the most common chronic illnesses. Despite the advancement in the management of heart failure, it still remains as one of the most important causes of mortality and morbidity. Anemia is a common finding in heart failure patients and decreases both life quality and bodily function in this group of patients. It is also related with high mortality and...
متن کاملBackground & Objective : Heart failure is a clinical syndrome and increases in rate by aging. Because changes in ECG and electrolytes are variable, specific and sometimes independent to the disease with different methods to be diagnosed, in this study we tried to find a way to diagnose them. Materials & Methods: This is a retrospective descriptive-analytic study. Data was collected from dec...
متن کاملارتباط محصولات نهایی Glycation پیشرفته با شدت نارسایی قلبی مزمن: بررسی 85 بیمار
Background: Advanced glycation end-products (AGEs) came up with the recent researches regarding new biomarkers for the diagnosis of heart failure. AGEs are the end products of non-enzymatic glycation and oxidation of proteins, lipids and nucleotides during Maillard biochemical reaction. Although it has been known that AGEs have a role in the pathogenesis of chronic heart failure (CHF), informat...
متن کاملبررسی تغییرات الکتروکاردیوگرافی، آنزیم‌های قلبی، قند خون و الکترولیت‌های سرم مبتلایان نارسایی قلبی جبران‌نشده بستری‌در بیمارستان
Background & Objective : Heart failure is a clinical syndrome and increases in rate by aging. Because changes in ECG and electrolytes are variable, specific and sometimes independent to the disease with different methods to be diagnosed, in this study we tried to find a way to diagnose them. Materials & Methods: This is a retrospective descriptive-analytic study. Data was collected from dec...
متن کاملPrognostic Value of Soluble ST2 (sST2) Serum Levels in Infants and Children with Heart Failure Complicating Congenital Heart Disease
Background Heart failure (HF) in infants and children with congenital heart disease (CHD) is a crucial complication with different outcomes. Many biomarkers are used as prognostic indicators. Soluble ST2 (sST2) is one of these markers studied in adults with HF. We aimed to study the prognostic value of sST2 in CHD children with HF. Materials and Methods In current case-control study, thirty-six...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Circulation
دوره 122 14 شماره
صفحات -
تاریخ انتشار 2010